Friday, November 13, 2026

Goldman Forecasts 7pp Big Tech ROE Decline as AI Capex Outpaces Returns

Goldman Sachs is forecasting a 7-percentage-point decline in Big Tech return on equity, warning that AI infrastructure spending has not yet translated into profitability gains. The bank published an AI spending and profitability report signaling institutional concern over the timing gap between capital outlay and revenue uplift. Analysts expect near-term derating of AI infrastructure stocks as margin compression accelerates.

LM Salvado
LM Salvado

June 17, 2026

Goldman Forecasts 7pp Big Tech ROE Decline as AI Capex Outpaces Returns
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Goldman Sachs is forecasting a 7-percentage-point decline in Big Tech return on equity, citing AI capital expenditure that is outpacing any measurable return on investment.1

The bank published a report on AI spending and profitability that doubled as a warning to institutional investors: AI infrastructure buildout is compressing margins before revenue uplift has arrived.1

Return on equity — the ratio of net income to shareholder equity — is the clearest measure of capital efficiency. A 7pp decline signals that AI investment is consuming capital faster than it generates profit. For large-cap technology companies already operating at high valuations, that dynamic creates material downside risk.1

The concern is structural, not cyclical. AI infrastructure requires sustained, multi-year capital commitments: data centers, chips, power infrastructure, and engineering headcount. Revenue from AI products — whether enterprise software, API access, or consumer subscriptions — accumulates more slowly and remains unevenly distributed across the sector.

Goldman's simultaneous publication of a spending report and a ROE forecast is itself a signal. It reflects a shift in how institutional analysts are framing AI: less as a growth catalyst and more as a capital allocation stress test.1

The near-term implication is stock derating. As institutional investors price in margin compression from AI spending cycles, Big Tech AI infrastructure names face valuation pressure even if underlying business fundamentals remain intact.1 Price-to-earnings multiples that were justified by AI growth expectations become harder to defend when ROE is declining.

For corporate finance teams inside these companies, the pressure is mounting to demonstrate returns. Internal hurdle rates, project prioritization, and capital allocation decisions are all being scrutinized against a backdrop of rising debt servicing costs and shareholder expectations that AI investment pays off within a foreseeable window.

The Goldman report does not suggest AI spending will stop — competitive pressure ensures it continues. What it signals is that the market's tolerance for open-ended AI capex without visible returns is narrowing. Investors are beginning to demand accountability metrics: revenue per dollar of AI infrastructure deployed, margin trajectory, and payback period.

That shift in investor posture, from endorsing AI spending to interrogating it, is itself a meaningful change in the capital markets backdrop for technology companies.1

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com